Company: XOMAP
Filing Date: 2025-10-03
Form Type: 424B5
Source: 0001193125-25-230383
Chunk: 26

Company: XOMA Royalty Corp
Filing Date: 2025-10-03
Form: 424B5
Chunk 26
---
 not held by us or any other person making such offer is converted or exchanged into other securities, cash or property; or |

| • |     | any reclassification of Common Stock or any compulsory share exchange by which our Common Stock is effectively 
 converted into or exchanged for other securities, cash or property (but not a reverse stock split).            |

If the holders of Common Stock are given a choice as to the securities, cash or property to be received in a fundamental transaction, the holders of Series X Preferred Stock will be given the same choice on conversion of such holders’ shares. Voting Rights.The Series X Preferred Stock has no voting rights, except to the extent expressly provided in our Articles of Incorporation or as otherwise required by law. However, so long as at least 50% of Series X Preferred Stock are outstanding, we may not take any of the following actions without the affirmative consent of holders of a majority of the outstanding Series X Preferred Stock:

| • |     | amend our Articles of Incorporation, Bylaws or other charter documents so as to materially, specifically and 
 adversely affect the preferences, rights, or privileges of the Series X Preferred Stock;                     |

| • |     | issue additional shares of Series X Preferred Stock or increase or decrease the number of authorized shares of 
 Series X Preferred Stock;                                                                                      |

| • |     | sell, assign, monetize, pledge or otherwise divest or encumber our rights under any material license agreement,                                
 joint venture or other partnership agreement to which we are a party as of the date of this offering and involving any drug or drug candidate; |

S-20

| • |     | issue or commit to issue any other equity securities, with certain exceptions; |

| • |     | issue any equity-based award or compensation to certain of our officers, unless the award has been unanimously                                     
 approved by our compensation committee at a time when a designee appointed by the Series X Preferred holders is then serving on that committee; or |

| • |     | enter into any agreement or understanding to take any of the actions listed above. |

Anti-Takeover Effects of Provisions of our Articles of Incorporation and Bylaws and Nevada Law Certain provisions of Nevada law, our Articles of Incorporation and our Bylaws could have the effect of delaying, deferring, discouraging or preventing another person from acquiring control of the Company. These anti-takeover provisions, which are summarized below, may have the effect of discouraging proxy contests and takeover bids. They are also designed,